Navigation Links
Researchers uncover some good news for BC's troubled salmon populations
Date:11/15/2012

Researchers uncover some good news for BC's troubled salmon populations

A University of Alberta led research team has some positive news for British Columbia's pink salmon populations, and the salmon farming industry that has struggled to protect both captive and wild salmon from sea lice infestations.

There has long been concern that concentrations of sea lice in BC's fish farming pens spread to wild fish stock in surrounding waters.

The researchers discovered that by changing the timing of sea lice treatments, one salmon farming region not only improved the health of their farm Atlantic salmon - the action has helped the struggling population of wild pink salmon to begin recovering.

The research was focused on salmon farming operations in one specific area of the BC coast, the Broughton Archipelago, which lies between the mainland and the northern tip of Vancouver Island. The researchers describe the area as the historic ground zero for studying the impacts of aquaculture on wild Pacific salmon.

Over the past decade, salmon farmers in the area have gradually shifted the timing of anti-parasite treatments to the fall and winter months. As a result, there have been fewer sea lice in coastal waters as juvenile pink salmon migrate to sea in the spring.

Researchers estimate that by 2009 the mortality from sea lice for juvenile pink salmon moving out to sea through the Broughton Archipelago fell to less than four per cent. This mortality estimate applies to the salmon that survive natural mortality such as predation.

During the early 2000's sea lice associated with the Broughton salmon farms had a devastating effect, killing an estimated 90 per cent of the migrating wild juvenile salmon that were left after natural mortality had taken its toll.

Lead U of A researcher Stephanie Peacock says because of their small size, juvenile pink salmon are highly susceptible to the effects of sea lice. During a period in their life cycl
'/>"/>

Contact: Brian Murphy
brian.murphy@ualberta.ca
780-492-6041
University of Alberta
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers use GPS tracking to monitor crab behavior
2. Researchers tap into CO2 storage potential of mine waste
3. Undersea gas leaks off Israels coast are discovered by University of Haifa researchers
4. Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy
5. Researchers to study impacts of pollutant nitrogen on plant species diversity
6. Autism Speaks announces the release of new genetic data for researchers
7. Making memories: Drexel researchers explore the anatomy of recollection
8. U-M researchers to study food security across Michigan
9. Researchers test solution to fungal disease of ash trees
10. UCLA researchers to study depression in breast cancer survivors
11. Princeton researchers identify unexpected bottleneck in the spread of herpes simplex virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... owned subsidiary, 3D-ID LLC, a company engaged in biometric ... the biometrics technology portion of the recently awarded TIES ... Department of the Army. 3D-ID LLC has ... government, law enforcement and security agencies. ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/10/2015)... May 11, 2015 Fingerprint Cards (FPC) ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... used by smartphone manufacturers in China . ... communicated revenue guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... 95 percent genomic similarity to humans, mice have long been ... Once researchers can shine a light on the genetic factors ... prevention and treatment options to protect the human population. ... difficult road, made more challenging by the 5% difference between ...
... shown that a dramatic sea-level rise occurred at the onset ... as the Blling warming, approximately 14,600 years ago. This event, ... rapid collapse of massive ice sheets 14,600 years ago and ... are published in the 29 March 2012 issue of the ...
... The Cardiovascular Cell Therapy Research Network (CCTRN), a ... Health,s (NIH) National Heart, Lung and Blood Institute (NHLBI) ... of its seven U.S. centers of excellence. The network ... over the next seven years to help achieve its ...
Cached Biology News:New lab mice cut search for genetic links to disease by more than a decade 2New lab mice cut search for genetic links to disease by more than a decade 3Ice sheet collapse and sea-level rise at the Boelling warming 14,600 years ago 2Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network 2
(Date:5/30/2015)... , May 30, 2015 CTI BioPharma Corp. ... Bioscience business (NYSE: BAX ) today announced data ... examining pacritinib for the treatment of myelofibrosis – in ... Meeting of the American Society of Clinical Oncology (ASCO), ... Pacritinib is an investigational oral multikinase inhibitor ...
(Date:5/29/2015)... In recent years, the biopharmaceutical industry has ... that can generate valuable insights. Despite this, the inherent ... have caused the biopharmaceutical sector to embrace Big Data ... According to a recent study by benchmarking firm, Best ... Data team or function in place; however, these organizations ...
(Date:5/29/2015)... May 29, 2015 Asthma ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading asthma ... fumarate) and Xolair (omalizumab), the global market for asthma ... end of the decade.   New analysis ...
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4
... Novagali Pharma, a French,pharmaceutical ophthalmic company, announces ... (IND) to conduct a Phase III clinical,trial ... glaucoma has been,granted by the U.S. Food ... ocular proprietary BAK-free formulation of latanoprost which,furthermore ...
... Milestone Payment from GlaxoSmithKlineMOUNTAIN VIEW, Calif., May 5 ... identified an orally bioavailable small molecule antagonist of ... clinical development. The acceptance of the molecule ... milestone payment from the alliance with GlaxoSmithKline (NYSE: ...
... May 5 Amylin Pharmaceuticals, Inc., (Nasdaq: ... LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) ... once weekly has been submitted to the U.S. Food and ... release medication for type 2 diabetes that is injected subcutaneously ...
Cached Biology Technology:Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 2Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 3Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 5Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 6Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 7